



ASX and MEDIA Announcement

## **MEDLAB receives UK Import Permission from MHRA for NanaBis™**

*This is in addition to previous announced approval for NanoCBD™*

**Sydney, November 25, 2022** - Medlab Clinical Ltd (ASX:MDC) (Medlab, the Company), an Australian biotech using delivery technology to enhance medicines effectiveness, is pleased to announce NanaBis™ (named NanaDol™ for UK purposes) has been approved by the UK Medicines and Healthcare Product Regulatory Agency (MHRA) for use in the UK Named Patient Program, and compassionate areas as an unapproved medicine, with WEP Clinical as their distribution partner.

NanaDol™ (alternative UK name for NanaBis™) will be provided to UK patients via doctor prescription for pain patients, including cancer bone pain, the therapeutic indication the company is most interested in.

WEP Clinical is a specialist services company that works with sponsors, to help patients and physicians gain early access to unregistered medicines as appropriate.

Like the Scheme Access Scheme (SAS) in Australia, patients will be charged a “compassionate” price for access to the medicine.

Medlab today announces regulatory acceptance by the UK govt for NanaDol™ (the UK name for NanaBis™) to be used in the UK as an unapproved medicine for special needs.

Medlab is now clearing UK Home Office for the appropriate importation certification needed to physically freight NanaDol™. The product is already manufactured and awaiting shipment for potential January 2023 patient supply.

### **About NanaBis™**

NanaBis™ is being developed for cancer bone pain as this is a population with need of better pain management and is a relatively homogeneous cancer population that provides important characteristics conducive to successful new drug registration and commercialisation. Furthermore, extensive independent preclinical research has identified the active components of NanaBis™, THC and CBD, as being particularly effective for treating cancer bone pain and a published clinical trial carried out by Professor Stephen Clarke at RNSH showed that Bone Cancer pain patients received a strongly clinically significant (40%) reduction in pain from NanaBis™.

### **About UK**

UK is a NanaBis™ clinical trial territory and obtaining Market Authority for NanaBis™ in the UK is a priority. Pre-Market Authority sales of NanaBis™ not only helps patients suffering from chronic pain unsatisfactorily treated by current options, but also provides the UK regulatory bodies (such as the MHRA) with Real World Data on the safety, tolerability and efficacy of NanaBis™ in UK-specific population, and generates patient advocates and key opinion leaders. It will also further demonstrate a real demand for NanaBis™ and provide valuable data to guide our clinical trial program.

**- ENDS -**

**Authorisation & Additional information**

This announcement was authorised by the Board of Directors of Medlab Clinical Limited.

**About Medlab Clinical:**

Medlab Clinical LTD (ASX:MDC) is pioneering the use of NanoCelle® a proprietary, patented delivery technology using water soluble nanoparticles®, allowing for enhanced medical properties, including increased efficacy, safety, patient compliance and stability.

Medlab's investigative drug pipeline comprises several small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies.

Patented lead drug candidate NanaBis™ is being developed for cancer bone pain as a viable alternative to opioid use. Data to date, strongly suggests NanaBis™ may be equally effective in non-cancer neuropathic pain. Medlab operates in Australia (Head Office), USA, and the UK.

For more information, please visit [www.medlab.co](http://www.medlab.co)

**Medlab** – *better medicines, better patient care*

**For further information contact:**

Dr. Sean Hall, CEO, Medlab Clinical Ltd

T: +61 411 603 378

E: [sean\\_hall@medlab.co](mailto:sean_hall@medlab.co)